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Abstract
Background: Epilepsy is a common and debilitating consequence of traumatic brain injury (TBI). Seizures
contribute to progressive neurodegeneration and poor functional and psychosocial outcomes for TBI survivors, and
epilepsy after TBI is often resistant to existing anti-epileptic drugs. The development of post-traumatic epilepsy (PTE)
occurs in a complex neurobiological environment characterized by ongoing TBI-induced secondary injury
processes. Neuroinflammation is an important secondary injury process, though how it contributes to
epileptogenesis, and the development of chronic, spontaneous seizure activity, remains poorly understood. A
mechanistic understanding of how inflammation contributes to the development of epilepsy (epileptogenesis) after
TBI is important to facilitate the identification of novel therapeutic strategies to reduce or prevent seizures.
Body: We reviewed previous clinical and pre-clinical data to evaluate the hypothesis that inflammation contributes
to seizures and epilepsy after TBI. Increasing evidence indicates that neuroinflammation is a common consequence
of epileptic seizure activity, and also contributes to epileptogenesis as well as seizure initiation (ictogenesis) and
perpetuation. Three key signaling factors implicated in both seizure activity and TBI-induced secondary
pathogenesis are highlighted in this review: high-mobility group box protein-1 interacting with toll-like receptors,
interleukin-1β interacting with its receptors, and transforming growth factor-β signaling from extravascular albumin.
Lastly, we consider age-dependent differences in seizure susceptibility and neuroinflammation as mechanisms
which may contribute to a heightened vulnerability to epileptogenesis in young brain-injured patients.
Conclusion: Several inflammatory mediators exhibit epileptogenic and ictogenic properties, acting on glia and
neurons both directly and indirectly influence neuronal excitability. Further research is required to establish causality
between inflammatory signaling cascades and the development of epilepsy post-TBI, and to evaluate the
therapeutic potential of pharmaceuticals targeting inflammatory pathways to prevent or mitigate the development
of PTE.
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Background
Epilepsy is a common and debilitating consequence of
traumatic brain injuries (TBI), with recurrent spontan-
eous seizures contributing to progressive neurodegener-
ation and greatly interfering with quality of life as well
as increasing the risk of injury and death. Epileptogen-
esis, the neurobiological process by which epilepsy
develops, occurs as part of the ongoing secondary injury
events triggered by a brain insult, including neuroin-
flammation. Previous evidence from clinical and pre-
clinical studies has suggested that aspects of the
inflammatory response may also promote seizure activity
itself (ictogenesis).
The aim of this review was to evaluate the published
evidence regarding the role of inflammation in the de-
velopment of post-traumatic epilepsy (PTE), drawing
upon data from both clinical studies and experimental
models. In particular, we summarize the current under-
standing of mechanisms by which neuroinflammatory
mediators can influence neuronal excitability, either
directly or indirectly. We focused in particular on three
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key signaling pathways which are known to be involved
in TBI-induced secondary pathogenesis, and more re-
cently, have been implicated in seizure activity and the
process of epileptogenesis. Lastly, potential mechanisms
underlying age-specific vulnerability to hyperexcitability
and epileptogenesis are discussed. This review also acts
to highlight knowledge gaps in the field, identifying key
areas for future research. Ultimately, a mechanistic un-
derstanding of how neuroinflammation contributes to
the development of epilepsy after brain injury may
identify novel therapeutic targets, to reduce or prevent
PTE for survivors of brain injuries.
Traumatic brain injury and epilepsy
TBI is a major global public health problem and a
leading cause of mortality and morbidity [1, 2]. It is
particularly prevalent in childhood and adolescence, as a
result of falls, inflicted trauma, sports-related injuries,
and motor vehicle accidents. An earlier review of 11
studies examining TBI incidence in Australia, North
America, and Europe estimated a median of 691 injuries
per 100,000 population under 20 years of age [2]. Of
note, children under the age of 5 had the highest inci-
dence of Emergency Department admissions for TBI [2].
TBI is any insult to the brain from an external mech-
anical force, including penetrative or blunt trauma [1, 3].
These can include focal injuries, such as lesions caused
by contusions or hemorrhages, or diffuse injuries, such
as with traumatic axonal injury [4]. TBI involves a
primary insult, defined as the immediate structural
damage caused by the external mechanical force. This is
followed by a secondary injury, which includes a myriad
of neuropathological processes including excitotoxicity,
neuroinflammation, oxidative stress, and apoptosis [1, 3,
5]. These secondary processes commence within mi-
nutes after TBI, can persist for months to years, and are
thought to contribute to the expansion of tissue damage
[6, 7]. The manifestation and severity of secondary injury
processes can differ depending on injury type, severity,
and individual factors [8]. The biomechanics and
biochemical components of the physiological response
to TBI have been reviewed in detail elsewhere [7, 9].
PTE is a common consequence of TBI, defined as
spontaneous, recurrent, and chronic seizures following a
head injury [10, 11]. Clinical diagnosis is often based
upon one or more unprovoked seizures occurring later
than 1 week after a TBI, as an indicator that epileptogen-
esis is occurring [12]. Epileptogenesis is the process by
which epilepsy develops; that is, when an otherwise
normally functioning brain becomes biased towards ab-
normal recurrent electrical activity, increasing the pro-
pensity to develop spontaneous recurrent seizures [13,
14]. It is thought to develop through three phases: (1)
the initial trigger; (2) the latency period, during which
the changes initiated in phase one cause a transform-
ational bias in the brain towards epileptic activity; and
(3) the onset of spontaneous seizures and the establish-
ment of chronic epilepsy (Fig. 1) [15–18]. After TBI, the
Fig. 1 Summary of the progression of inflammatory factors and epileptogenesis after TBI. After TBI, epileptogenesis occurs after a latent period of
months to years. Within hours after the injury, a myriad of cytokines are released at high levels which can continue for days. This is concurrent with
activation of ion-channels and post-translational modifications of various receptors associated with neuronal excitation and inhibition, which can occur
as early as minutes after the injury. Local immune cells are activated, and peripheral immune cells are also recruited to the area within hours to days.
Neuroinflammation can persist for weeks after the injury, coincidental with widespread neuronal loss. In the later phase of epileptogenesis, processes
such as neurogenesis and mossy fiber sprouting in the hippocampus contribute to an increasingly excitable neuronal environment. It may be weeks,
months, or years before spontaneous seizures and the establishment of chronic and persistent epilepsy manifests
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latency period may be many years in duration, and epi-
leptogenesis is associated with ongoing secondary injury
processes which can bias towards hyperexcitability [14].
The reported incidence of developing epilepsy after
TBI ranges from 4.4 to 53%, depending on the popula-
tion studied [12]. There are several factors that have
been associated with a greater risk of developing PTE,
including higher injury severity and a lower age-at-insult
[10, 19, 20]. It has been estimated that 10–20% of
children with severe TBI develop PTE, although the risk
after injury has been reported at up to 60%, with the
wide range of estimates most likely due to the large vari-
ation in severity, heterogeneity of the initial insult, and
difficulties in diagnosis and follow-up [10, 20]. Children
under the age of 5 may be at highest risk for early post-
traumatic seizure development [10, 12, 21], with one
study finding that this age group were more likely to
have a seizure within the first week after injury (17%),
compared to patients over 5 years of age with similar in-
juries (2%) [22]. In adults, the presence of acute intrace-
rebral hematoma has been consistently associated with a
higher risk of developing PTE, as are penetrative insults
and depressed skull fractures [12, 22, 23].
Several neuropathological hallmarks have been associ-
ated with the development of PTE. An early and persist-
ent increase in hippocampal excitability has been
observed in both patients and animal models [24]. This
net increase in excitability is thought to result from the
selective loss of vulnerable inhibitory interneurons con-
current with the reorganization of excitatory circuitry
[25, 26]. Recurrent excitatory circuitry in the hippocam-
pal dentate gyrus may manifest as mossy fiber sprouting,
where the axons of dentate granule cells form abnormal
connections with neighboring neurons in response to a
loss of CA3 pyramidal cell targets and hilar interneurons
[27, 28].
The onset of PTE is also commonly associated with
hippocampal sclerosis, involving the loss of pyramidal
neurons, and concurrent reactive gliosis, consistent with
temporal lobe epilepsy (TLE) [29]. An estimated 35–62%
of patients with PTE have seizures originating from the
temporal lobe [30, 31]. However, overlaying cortical
regions have also been implicated in post-TBI epilepto-
genesis, as these regions may also exhibit neuronal loss,
chronic neuroinflammation, and network reorganization
resulting in spontaneous epileptiform activity [26, 32].
Clinical management and treatment of PTE is challen-
ging, as seizures are commonly resistant to existing anti-
seizure drugs (ASDs) [10, 20, 33, 34]. Classical ASDs,
such as phenytoin, carbamazepine, valproate benzodiaze-
pines, are ineffective in reducing or preventing PTE
[34–36]. While early post-injury prophylaxis with ASDs
may reduce or prevent early post-injury seizures [37],
there is little evidence to indicate that these treatments
can be disease-modifying and prevent the development
of PTE or spontaneous unprovoked seizures long-term
[38]. Once a patient has developed seizures, polyphar-
macy is often employed in an attempt to control the
seizures, yet a significant proportion of TBI patients who
develop epilepsy will develop drug-resistance, defined as
a failure to achieve seizure cessation after trialling more
than two tolerated and appropriate ASD treatments [33,
34]. However, the use of multiple ASDs simultaneously
could have unpredictable consequences due to potential
interactions with various secondary processes and the
reduced cerebral perfusion commonly present after TBI
[20]. Seizures are particularly detrimental during periods
of brain development as they can cause permanent
adverse effects, including cognitive deficits [39, 40]. Due
to increased susceptibility to post-traumatic seizures
after an early age-of-insult, as well as inherent difficulties
in controlling or treating PTE, further research is needed
to understand the mechanisms that contribute to the
generation of post-traumatic seizures, particularly in
pediatric age groups.
Neuroinflammation after TBI
Inflammation is a central component of the secondary
injury after TBI, and the subject of intense research as a
promising target for treatment. In healthy tissue, inflam-
mation typically acts to combat invading pathogens and
preserve the health of the tissue [41]. However, in patho-
logical conditions such as trauma, inflammation can also
function as a reactionary system to either aggravate or
ameliorate tissue damage [42, 43]. Increased neuroin-
flammation after TBI has been associated with poor
outcomes and progression to various sequelae including
neurodegenerative diseases [43–47].
The main hallmarks of the cerebral inflammatory
response after TBI include blood-brain barrier (BBB)
dysfunction, edema, microglial, and astrocytic activation
and migration, the release of inflammatory factors such
as cytokines and the recruitment of blood-derived leuko-
cytes into brain parenchyma [48]. Neutrophils, recruited
from the peripheral circulation within hours after TBI,
mediate early pathogenesis by promoting edema and
oxidative stress, and the production of inflammatory
cytokines and neurotoxic proteases [49, 50]. Cytokines
can be released rapidly after injury as they are synthe-
sized and stored locally by neurons and glia [48].
Under physiological conditions, the BBB is a highly
stringent barrier between vessels and brain tissue,
which mediates the transport of blood components
such as immune cells into the brain [51]. After TBI,
this barrier can be compromised, allowing peripheral
inflammatory cells into the brain and the injured area
[52]. Chemoattractant cytokines, called chemokines,
further facilitate the recruitment and transmigration
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of inflammatory leukocytes [53]. By their actions at
the BBB as well as direct chemoattraction, chemo-
kines including CXCL8 and CCL2 (also known as
monocyte chemoattractant protein-1) are key media-
tors in the migration of neutrophils and monocytes,
respectively, to the site of injury [54].
Once in the brain, these cells release a plethora of inflam-
matory cytokines, chemokines, and reactive oxygen species
(ROS) to perpetuate inflammation and oxidative stress in
the injured brain. Both clinical and experimental studies
have demonstrated a pronounced elevation of many cyto-
kines after TBI, including tumor necrosis factor (TNF-α),
transforming growth factor-β (TGF-β), and interleukin-1β
(IL-1β), -6, and -10, with downstream activation of intracel-
lular signaling cascades involving nuclear factor Kappa-
light-chain-enhancer of activated B cells (NF-κB) [1, 44, 48,
55–57]. Released cytokines in turn can recruit additional
blood-borne neutrophils and monocytes into the injured
tissue, propagating the inflammatory cascade.
Inflammation in the brain has a duality in function
after injury, which manifests through the actions of
many different cell types. For example, microglial
activation is integral in tissue repair, surveillance of
pathogenic factors and host defense [58]. However,
activated microglia can also release cytotoxic factors
such as ROS to induce oxidative stress [59–61]. As-
trocytes can promote tissue repair in the central ner-
vous system (CNS) through the release of insulin-like
growth factor [47], but are also implicated in the per-
petuation of inflammation by an over-production of
cytokines such as IL-6 [62, 63], as well as modulation
of the BBB and neuronal function to promote excit-
ability and seizure production [64].
Cytokines themselves also have a complex role after
TBI, as experimental studies have yielded conflicting
findings of both deleterious contributions and partici-
pation in repair processes after CNS insult [48]. One
cytokine that displays such paradox is TNF-α, which
has been associated with increased neurological
damage, including demyelination and BBB breakdown,
in several experimental models of TBI [65, 66]. How-
ever, increased levels of TNF-α may conversely have a
neuroprotective function in the late stages of inflam-
mation post-TBI, at 2–4 weeks after the injury, as
suggested from a mouse model of TBI [56]. The
varied roles of inflammatory mediators in the patho-
logical environment after TBI is likely dependent on
many different factors, including timing of release,
the location and cell types involved, the differing
physics of protein-protein interactions of cytokines,
and their relative amounts. The multifarious dynamics
of this response may contribute to the progression of
a chronic state of damage, leading to the myriad of
secondary consequences of TBI, including PTE.
Inflammation in epileptogenesis
The long-standing concept that seizures result from an
imbalance between reduced γ-aminobutyric acid
(GABA)-ergic inhibition and enhanced glutamatergic ex-
citation [67, 68], based upon the presence of large ampli-
tude EEG discharges during the seizure event itself, is an
over-simplified of a very complex network response.
While excessive glutamatergic excitation has historically
been considered of as the precipitating factor for a focal
seizure, there is a lack of strong data to support this
hypothesis. Instead, paradoxically, accumulating evi-
dence indicates that increased synchronised GABAergic
interneuronal activity is sufficient to disrupt neuronal
networks and initiate the transition from interictal to
ictal activity resulting in focal seizures [69]. The recruit-
ment of neighboring neurons and subsequent seizure
progression is then hypothesized to be mediated by an
elevation in extracellular potassium [70]. Adding to the
complexity of network-based activity, both excitatory
and inhibitory roles of GABA and glutamatergic neurons
have been reported, and a range of extrasynaptic as well
as synaptic neurotransmitter receptors and ion channels
have been implicated in seizures, in addition to those
traditionally implicated, such as NMDA and GABAA
receptors [71].
However, strong evidence also implicates a role for in-
flammation in seizure pathologies [45]. Seizure activity
readily induces an inflammatory response, including the
activation of microglia and production of pro-
inflammatory cytokines [47, 63]. More importantly,
experimental data has suggested that inflammatory me-
diators may initiate or trigger early seizures, preceding
the onset of diagnosed epilepsy. For example, systemic
inflammation by injection of bacterial lipopolysaccharide
results in a lowered seizure threshold [72]. In the next
sections, we will review clinical and experimental
evidence suggesting an inherent link between inflamma-
tory signaling, neuropathology, and seizure activity in
the injured brain, as a likely mechanism of importance
in the development and progression of PTE.
Seizures increase inflammation
Experimentally, induction of a seizure induces the rapid
activation of glial cells in surrounding parenchyma,
which respond by the production and release of inflam-
matory molecules [73]. Much of the research that has
shown an increase in inflammation after seizures have
used experimental models of status epilepticus. This
involves the administration of a chemical or electrical
pro-convulsant stimulus to create a sustained seizure
event (the initial insult) followed by a latency period be-
fore the onset of spontaneous recurrent seizures to
model epilepsy [74, 75]. In these experimental models,
the inflammatory response displays a distinct temporal
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profile after induction, characterized by the early activa-
tion of astrocytes and microglia followed by BBB
breakdown and neuronal activation [63, 76, 77]. In
addition to the investigation of protein release, micro-
array analysis of gene transcripts have also demonstrated
an upregulation of inflammatory genes [78]. Specific cell
surface toll-like receptors (TLR’s), which respond to a
range of inflammatory cytokines and other stress-related
factors, are highly upregulated after pilocarpine-induced
seizures on forebrain microglia of adult mice [77].
Simultaneously, a robust increase in cytokine levels has
been observed in both chemically and electrically
induced experimental models of epilepsy in adult ro-
dents [77, 79, 80]. For example, IL-1β is expressed at
low levels in a healthy brain, but is robustly upregulated
for up to 60 days after the induction of self-sustaining
limbic status epilepticus in rodents, a model using hip-
pocampal electrical stimulation [76]. TNF-α and IL-6
are also rapidly upregulated after status epilepticus,
peaking within 30 min of seizure onset and remaining
elevated for up to 72 h in rats that progressed to
spontaneous seizures [76].
These experimental findings that seizures result in in-
flammation are confirmed by evidence in the clinical
setting. Analysis of cerebrospinal fluid (CSF) from newly
diagnosed adult patients with tonic-clonic seizures
detected an upregulation of IL-6 and IL-1 receptors (IL-
1Rs) [81, 82]. Matched serum samples revealed a higher
levels of IL-6 compared to in the CSF, suggesting that
these cytokines likely originated in the brain [82]. High
levels of cytokines including IL-1β and high-mobility
group box protein-1 (HMGB1) have also been identified
in neurons and glia of surgically resected epileptic tissue
[83]. Together, these findings indicate that neuroinflam-
mation is a common consequence of seizure activity.
Inflammation contributing to seizures
Accumulating evidence suggests that neuroinflammation
is also a contributor to epileptogenic pathology after TBI
[45, 63, 84]. In particular, experimental models have
demonstrated that glial cell activation and recruitment
and the synthesis of inflammatory factors, may precede
and/or occur concurrently with epileptogenic events [85,
86]. For example, in a rodent model of experimental
TBI, a reduced threshold to electroconvulsive shock-
induced seizures was reversed when minocycline, a
tetracycline antibiotic known to inhibit brain infiltration
of monocytes and microglia, was applied [87, 88], impli-
cating both microglial activity and pro-inflammatory
cytokines in post-traumatic seizure activity.
Much of the evidence for a role of inflammation in
epileptogenesis has focused on the effect of cytokines in
seizure susceptibility. Cytokines can act as classical
neurotransmitters through receptor modulation and
phosphorylation at the neuronal membrane [89]. Models
of chronic inflammation, such as transgenic mice
systemically overexpressing IL-6 or TNF-α, can reduce
seizure threshold and predispose the brain to seizure
induced-neuronal loss [90, 91]. Indeed, inflammatory sig-
naling may promote the loss of GABAergic neurons in the
hippocampus, resulting in an increased propensity for
seizures due to a reduction in synaptic inhibition [92].
N-methyl-D-aspartate (NMDA) receptors play a crit-
ical role in the glutamatergic system to contribute to
neuronal excitability, and previous evidence suggests
both direct and indirect interactions between these
receptors and cyokines [93]. Cytokines have been found
to inhibit the uptake of glutamate by astrocytes in
culture [94] and modulate excitatory neurotransmission
in the brain through NMDA and alpha-amino-3-hy-
droxyl-5-methyl-4-isoxazole-propoinate (AMPA) recep-
tors [95, 96]. For example, IL-1β produced by microglia
can enhance NMDA-mediated Ca2+ currents through
cell surface type 1 IL-1R (IL-1R1) co-localized on pyr-
amidal cell dendrites [89]. Pre-synaptic NMDA receptors
are agonists for Ca2+-mediated glutamate release, and
when activated by inflammatory factors such as IL-1β
and HMGB1 can cause an excess of intracellular Ca2+
leading to an extracellular hyperexcitability and excito-
toxicity [95]. Several other cytokines including TNF-α
and IL-10 have also been associated with the regulation
of seizure duration in experimental kindling models [97,
98]. Though these correlations have been seen in mul-
tiple studies with different models, the mechanisms
underlying the relationship between the inflammatory
environment and epileptogenesis, particularly in the
context of brain injury, remain still poorly understood.
There is limited clinical data to confirm a cause-and-
effect link between inflammation and the pathophysiology
of epilepsy, however increasing evidence supports this hy-
pothesis. Many studies have now demonstrated that early
exposure of the brain to immune responses can have
varied and persistent consequences on adult physiology
[99–102]. Febrile seizures (FS) and febrile status epilepti-
cus in children is a risk factor for developing epilepsy later
in life [103], which may be induced by fever often associ-
ated with inflammation and infection [47]. Although the
mechanisms underlying FS remains unclear, it is thought
that cytokines play a key role in its development [104].
One study has reported specific polymorphisms in the
promoter region of cytokine genes, including IL-1β, in
children with FS compared to controls [105]. Such genetic
variation may influence the production of IL-1β in both
healthy tissue and after injury or stimulus [106], and simi-
lar polymorphisms have also been observed at a high
frequency in patients with TLE [107].
Recently, the hypothesis of glial functions playing a
pivotal role in biasing the neuronal network towards an
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epileptogenic environment has been gaining traction
[108, 109]. In particular, interactions between neurons,
glia, and the inflammatory mediators IL-1β, HMGB-1,
and TGF-β, have been implicated in promoting seizure
susceptibility, as described below. The main signaling
pathways implicated in the proposed link between
inflammation and epileptogenesis of these three
mediators is summarized in Fig. 2.
IL-1β/IL-1R signaling in TBI and PTE
IL-1 is a family of pro-inflammatory cytokines that
act as key mediators of the innate immune response
[110]. The IL-1 family consists of 7 agonists (e.g.,
IL-1α and β) and 3 receptor antagonists [110], and
amongst these the IL-1β isoform has been the most
commonly studied in the brain injury and epilepsy
settings. In the CNS, IL-1β can be produced by a
range of cells including microglia, astrocytes, endo-
thelial cells (EC), neurons, and peripheral leukocytes
upon infiltrating into the brain [111–113]. IL-1β
exerts its action on multiple cell types primarily via
IL-1R1 [114–119]. This initiates intracellular signal-
ing via NF-κB transcription factor, p38 mitogen-
activated protein kinase (MAPK), or other factors
[118, 120]. Several studies have demonstrated that
IL-1β binding to IL-1R stimulates immune cell
activation and induces the production of neurotoxic
molecules [114, 115, 117–119].
Fig. 2 Summary of three key signaling cascades that may mediate the link between inflammation and epileptogenesis. HMGB1, IL-1β, TGF-β, and
serum albumin have varied release mechanisms from multiple cell types in order to activate their signaling pathways. After injury, HMGB1 may be
passively released from necrotic neurons to the extracellular space, or released actively from activated microglia and astrocytes. HMGB1 can bind
to multiple receptors on many different cell types, such as TLR4, which can activate MyD88 independent pathways such as the phosphorylation
of interferon regulatory transcription factor 3 (IRF3) leading to the transcription and release of interferons-α and -β, as well as other interferon-induced
genes. HMGB1-TLR4 can also activate NF-κB signaling both directly or via TNF receptor-associated factor 6 (TRAF6). This can lead to a rapid nuclear
transcription of various immune-related processes, as reviewed elsewhere [250]. Caspase-1 mediates cleavage of inactive pro-IL-1β to active IL-1β,
allowing for its relocation into the extracellular space, where IL-1β can bind to IL-1R1 either directly or in complex with HMGB1. The IL-1β/IL-1R1
complex can then induce NF-κB signaling via TRAF6 or activate MyD88-dependent MAPK signaling, which has been linked to the production of various
neurotoxic molecules. TGF-β is released in an inactive form from cells and binds to the extracellular matrix. Proteases, released after injury, cleave the
inactive protein to active TGF-β, which is able to bind to the two TGF-β receptors. Mechanical breakdown of the BBB allows serum albumin into the
extracellular space, where it can also bind to TGF-β receptor1 and receptor2, which signal via Smad complex proteins or MAPK signaling pathways,
respectively, to regulate the immune response. This pathway has also been implicated in post-translational changes to a variety of voltage-dependent
ion channels implicated in changes to neuronal excitability [94]
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There are several lines of evidence implicating IL-1β
in the development of PTE. Firstly, IL-1β is rapidly and
highly upregulated following experimental and clinical
TBI. In rodent models, Il-1β expression is upregulated
as early as 1 h post-TBI [121, 122] and peaks between 12
and 24 h [54, 123, 124]. This response may then persist
for several months post-injury [125]. Consistent with ex-
perimental findings, analysis of protein, and gene expres-
sion in post-mortem brain tissue from TBI patients
found that IL-1β was upregulated in individuals who
died 6–122 h post-injury [126]. This is consistent with
reports of elevated IL-1β in the CSF and serum of severe
TBI patients [127, 128], correlated with poor outcomes
in both children and adults [19, 129]. Thus IL-1β levels
are elevated during the period of secondary injury after
TBI, which has been postulated to also be an important
time period for the epileptogenic process [130]. Notably,
numerous studies indicate that modulating IL-1β signal-
ing is broadly beneficial in experimental TBI models.
Treatment with an IL-1β neutralizing antibody alleviated
TBI-induced microglial activation, neutrophil infiltra-
tion, cerebral edema, and cognitive deficits in mouse
models of TBI [131, 132]. In line with this finding, IL-
1R1 deficient mice also showed decreased cerebral
edema and leukocyte infiltration following TBI [133],
and post-injury administration of an IL-1R1 antagonist
attenuated neuronal cell death and cognitive dysfunction
in rats [134]. A phase II clinical trial employing an IL-1R
antagonist treatment (100 mg/day subcutaneously ad-
ministered for 5 days) was recently conducted in
patients with severe diffuse TBI, demonstrating safety
penetration into the plasma and brain extracellular fluid,
and an alteration of the immune profile [135].
One of the key clinical studies linking IL-1β with PTE
was conducted by Diamond and colleagues, who exam-
ined whether genetic variation in the IL-1β gene and
CSF/serum IL-1β ratios correlated with PTE develop-
ment in a cohort of 256 patients with moderate to severe
TBI [136]. Serum and CSF were collected from a portion
of subjects within the first week post-injury, and IL-1β
levels were assessed in relation to the later incidence of
PTE. Further, IL-1β tagging and functional single nu-
cleotide polymorphisms (SNPs) were genotyped to
evaluate its association to PTE. Elevated CSF/serum
IL-1β ratios were found to be associated with increased
risk of PTE, and one of IL-1β SNPs, rs1143634, showed
an association between the heterozygote genotype and
increased PTE risk [136]. Further research is required to
determine the contribution of genetic variability to IL-1β
function and how this may influence the inflammatory
response after TBI.
IL-1β has also been linked to other epilepsies in addition
to PTE. For example, IL-1β may play a role in epilepto-
genesis that follows FS. Specifically, IL-1β levels were
found to be acutely upregulated in rats after prolonged FS,
and IL-1β levels remained elevated only in rats that devel-
oped spontaneous limbic seizures after prolonged FS
[137]. In another study, IL-1R1 deficient mice were found
to be resistant to experimental FS [138].
There are a number of possible mechanisms by which
IL-1β may contribute to PTE. IL-1β can modulate neur-
onal hyperexcitability through Ca2+, glutamatergic, and
GABAergic pathways [139]. By acting on glia cells, IL-1β
mediates astrocytes and microglia activation, formation
of a glial scar, and the release of neurotoxic mediators to
promote cell loss, features which are associated with epi-
leptic foci in the brain [140]. Furthermore, IL-1β signal-
ing may promote epileptogenesis by enhancing BBB
permeability and enhancing the recruitment of periph-
eral leukocytes into the brain [141–144]. There are many
proposed mechanisms of IL-1β signaling in areas that
are still poorly understood, and future research into
these may reveal the way in which they interact to in-
crease the risk of epileptogenesis.
Although less commonly studied, other members of
the IL-1 family have also been investigated in the con-
text of TBI and epilepsy. For example, an upregulation
of IL-1α has been reported in brain tissue following ex-
perimental TBI [145, 146]. In the clinical setting, periph-
eral blood mononuclear cells collected from epilepsy
patients exhibited greater production of IL-1α in re-
sponse to stimulation in vitro compared to cells from
non-epileptic controls [147]. However, no association
has been found between gene polymorphisms of IL-1α
and TBI outcomes [148], nor IL-1α and seizure patho-
genesis [149]. Taken together, there is much accumulat-
ing experimental and clinical evidence implicating IL-1
cytokines in epileptogenesis, however further studies are
needed to delineate their precise roles and whether
therapeutically targeting them can mitigate PTE.
HMGB1/TLR4 signaling in PTE
HMGB1 was originally identified as a ubiquitous, highly
evolutionarily conserved, chromatin-binding protein,
most often found in the cell nucleus of healthy tissues
[150–152]. Discovered in 1973, and named due to its
ability to migrate quickly during gel electrophoresis
[153], HMGB1 participates in the formation of nucleo-
somes and is important in the regulation of gene tran-
scription [151, 154, 155]. More recently, HMGB1 has
been identified as a damage-associated molecular pattern
(DAMP) [150], which are molecules that are able to ini-
tiate or perpetuate inflammation. Complete gene defi-
ciency of HMGB1 is lethal during early postnatal life,
indicating its essential role in transcriptional control
[156]. A 98% homology between human HMGB1 and
mouse HMGB1 enables clinically relevant experimental
investigation through animal models [157].
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HMGB1 has two modes of cellular release in injured tis-
sue. Immediately after injury, necrosis allows a passive re-
lease of significant amounts of HMGB1 from the nucleus
into the extracellular space [158]. HMGB1 may undergo
post-translational oxidation and acetylation, resulting in
its active release by immune cells in response to various
cytokines including itself, allowing a powerful positive
feedback loop during inflammation [157, 159–161]. In
addition, HMGB1 may be released upon activation by a
wide range of cells in the CNS including neurons, micro-
glia, macrophages, monocytes, natural killer cells,
dendritic cells, ECs, and platelets [162].
High levels of HMGB1 have been found in epilepto-
genic tissue resected during surgery [83, 163], implicat-
ing a role for this DAMP in neuronal hyperexcitability.
Experimental evidence from an animal model of tem-
poral lobe epilepsy suggests that HMGB1 contributes to
seizure activity and epilepsy [164]. One previous study
by Maroso and colleagues demonstrated that intracere-
bral injection of HMGB1 in wild type mice increased
seizure activity in response to a stimulus [165]. This
pro-convulsant effect of HMGB1 is most likely mediated
through one of its key signaling receptors, TLR4, as a
comparable increase in seizure susceptibility was not
seen in non-functional TLR4 mutant mice [165]. TLR4
mutant mice were also found to be intrinsically resistant
to seizures as compared to wild type mice [165]. Inter-
fering with the binding of HMGB1 to TLR4 has been
shown to reduce both seizure frequency and onset. For
example, TLR4 antagonists and BoxA, a competitive an-
tagonist to HMGB1 comprising of the BoxA domain of
the protein, have been reported to reduce and even in-
hibit epileptic activity that is resistant to standard ASDs
in an animal model of temporal lobe epilepsy [166].
In another recent study, the mechanism by which
HMGB1 signaling promotes neuronal hyperexcitability
and seizure activity was found to be through an increase
in NMDA receptor function in TLR4-expressing hippo-
campal neurons [167]. This effect was dependent on the
oxidation of HMGB1 characteristic of its active release
from immune cells, and was associated with high levels
of NMDA-induced excitotoxic cell death [167]. Because
the inflammatory environment after TBI involves the
rapid production of ROS and free radicals [168, 169],
there is a physiological preference towards the extracel-
lular oxidation of HMGB1, thus increasing TLR4-
mediated augmentation of NMDA functionality and
promoting seizure susceptibility [167].
Downstream of HMGB1, TLR4 mRNA expression is
upregulated in response to brain insult [170], consistent
with upregulation of this receptor during seizure activity
in experimental models of epilepsy [165]. TLR4 is able
to transmit signals via both myeloid differentiation pri-
mary response gene 88 (MyD88) dependent and
independent pathways [171]. It is through the MyD88
dependent pathway that TLR4 is able to activate NF-κB,
which may be responsible for increasing pro-inflamma-
tory cytokine expression to augment the inflammatory
response [172, 173]. This pathway has generated great
interest recently, and with the potential to modulate epi-
leptic activity, even in drug-resistant epilepsy, further re-
search is needed to confirm the potential of this pathway
as a target for therapeutic intervention in the develop-
ment of PTE.
Previous research has also suggested that HMGB1 is
able to enhance inflammation through forming a com-
plex with different cytokines, including IL-1β [174].
HMGB1 bound to IL-1β has been isolated from cell
cultures when co-incubated [174]. Studies of joint in-
flammation in animals have also shown that when
HMGB1 is present with IL-1β there is an enhanced in-
flammatory response, most likely through action on with
IL-1 receptor 1[175], Whilst this complex has yet to be
identified in brain tissue, further research is needed into
this pathway as it may play a vital role in extending a
bias towards epileptogenesis.
By contributing to acute and chronic seizures, both
directly and indirectly, the HMGB1-TLR4 axis is there-
fore a promising target for TLEs that are resistant to
ASDs [165, 167]. This is important in the context of
TBI, as seizure pathology can begin as early as the day
of a brain injury [176]. Together, these data support a
key role for HMGB1 in neuronal hyperexcitability and
implicate the HMGB1-TLR4 signaling pathway as a
potential therapeutic target to modulate post-traumatic
epileptogenesis.
TGF-β/albumin involvement in PTE
Vascular dysfunction has been associated with many types
of focal and acquired epilepsies, including PTE [177]. BBB
dysfunction is also a common feature of TBI in both
patients and experimental models [6, 178]. Vascular
dysfunction after TBI, in particular the localized break-
down of the BBB surrounding focal regions of tissue
damage, is hypothesized to trigger a series of epileptogenic
processes [179]. For example, increased permeability of
the BBB is evident by magnetic resonance imaging with
gadolinium and co-localized with the focal epileptogenic
region in patients with PTE [180, 181].
A proposed mechanism of BBB breakdown in this
context is through the TGF-β/albumin-mediated signal-
ing pathway. In the laboratory, experimental opening of
the BBB in the rodent neocortex was found to trigger
epileptogenesis, which was recapitulated by exposure of
the brain to serum albumin [182]. Albumin has been
shown to induce the production of excitatory synapses
experimentally both in vitro and in vivo [183]. Serum
albumin in the rodent brain has been shown to result in
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hypersynchronized responses to electrical stimulation
[184], analogous to those observed in animal models of
epilepsy [185, 186]. The formation of epileptiform activ-
ity after albumin exposure is delayed, suggesting that the
mechanism of action is complex rather than a direct
effect by albumin [184]. One possible mechanism which
has been receiving scrutiny is the activation of astrocytes
by serum albumin [109, 187], activating a TGF-β
receptor-mediated signaling cascade [64, 182, 184].
TGF-β is a pleiotropic cytokine involved in various
cellular processes, including cell growth, differentiation,
morphogenesis, apoptosis, and immune responses
through intercellular communication in many different
cell types [188–190]. Signaling is mediated by binding of
TGF-β to two serine threonine kinase receptors, which
when activated cause the phosphorylation of the Smad
protein complex and the p38 MAPK pathway [191]. A
role for TGF-β has been implicated in many different
CNS diseases, related to its upregulation in Alzheimer’s
disease, multiple sclerosis, ischemic brain injury, and
TBI [192]. TGF-β is thought to have neuroprotective
properties, and is associated with both microglial activa-
tion and the wound healing response [193]. Paradoxic-
ally, TGF-β also appears to contribute to excitotoxicity,
adding to the dual role of inflammation which is
dependent on the context and cell types involved [194].
Further research into the variation in response from this
pathway is needed, as this may reveal insights into the
dual role of inflammation and how to bias the brain to-
wards neuroprotection rather than neurodegeneration.
The binding of albumin to TGF-β receptor has been
characterized experimentally in rodent models of BBB
disruption, resulting in the activation of TGF-β signaling
[184]. The induction of experimental BBB dysfunction to
induce epileptiform activity can be prevented through
blockage of albumin binding to TGF-β receptors [184].
Much of the published literature has focused on
albumin’s interaction with the TGF-β signaling pathway
in disease models, but there is some suggestion that
TGF-β may also play a role in PTE from animal models
with similar pathologies. In rodent models of epilepsy,
TGF-β is reportedly upregulated in both neurons [195]
and hippocampal astrocytes [196]. The action of TGF-β
in astrocytes following exposure to albumin has also
been shown to induce pro-ictogenic cytokine produc-
tion, resulting in increased neuronal excitability in ex-
perimental models [197]. TGF-β has also been
implicated experimentally in excitatory synaptogenesis
in a post-injury epilepsy model [183]. As neuronal
reorganization and synaptogenesis are hypothesized to
be a potential mechanism underlying chronic seizures
and are well-documented consequences of CNS trauma,
this action of TGF-β may be critical for the progression
of brain injury to epilepsy [183, 198, 199]. In summary,
the actions of TGF-β in the injured and epileptic brain
remain poorly understood, but the potentially
paradoxical behavior of this cytokine warrants further
investigation.
Age-specific vulnerability to PTE
Neuroinflammation is a key aspect of secondary injury
that can vary according to the stage of brain develop-
ment, which may underlie differences in clinical
outcomes between patients who suffer a TBI during
childhood and patients who suffer a TBI during adult-
hood [200]. Many studies now suggest that the early
postnatal brain has an enhanced propensity for
inflammation, described as a ‘window of susceptibility’
[200–202]. Early support for this hypothesis came from
experimental evidence that 3-week old (juvenile) rats
showed a higher susceptibility to IL-1β-induced BBB
breakdown compared to adult rats [203, 204]. These
observations are most likely not due to an immaturity of
the BBB integrity at a younger age, as the tight junctions
that maintain the BBB are fully developed from prenatal
stages [205], but rather to a unique global chemokine
expression profile that is distinctly different to the adult
CNS [200]. In experimental autoimmune encephalomy-
elitis, a model of multiple sclerosis that shares some of
the inflammatory processes of PTE, many chemokines
involved in the recruitment of T cells and monocytes
into the brain are robustly upregulated to 2–6-fold
higher in juveniles compared to adults, including CCL2,
CCL3, and CCL6 [200, 206–208]. There is also some
evidence in the clinical context that the response of the
immune system in the brain after a pathogenic challenge
also differs between adults and children, with children
presenting with higher production of IL-1 and IL-10
from peripheral blood monocytes after pathogenic
stimulation [209]. Several cytokines have been detected
at elevated levels in both CSF and serum of children
after TBI, including IL-1α, IL-6, IL-12, and TNF-α,
though how this response may correspond to the clinical
differences at different ages after TBI are still relatively
underinvestigated [210–212].
Microglia present differently within the immature
brain compared to adults. During early postnatal devel-
opment, their morphology is distinct, with fewer pro-
cesses than those in the adult brain [213], and in an
experimental pathogenic model, neonatal brain injury
induced a markedly reduced activation compared to the
robust activation seen in adult brain tissue [214].
Activated microglia typically adopt a phagocytic morph-
ology and are associated with neuronal death, which is
thought to be a critical aspect of normal brain
development [201, 215]. There are also more circulating
macrophages in the developing brain compared to adults
under basal conditions associated with dying neurons
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and glia, particularly in the corpus callosum [213, 216].
Neutrophil infiltration into brain parenchyma after
injury differs across ages, with a much higher level of
infiltration detected experimentally in postnatal day 7
(p7) rats than in adults [214]. This neutrophil infiltration
can persist 2–3 days after a pathogenic challenge and
was found to be concurrent with damage to vasculature
[203, 204, 214].
Increased seizure susceptibility in the immature brain
may result from several contributing factors. Glutamate
is the primary neurotransmitter in both the adult and
developing brain [217], yet there is low expression of the
glutamate type 1 transporter, therefore, clearance from
the synaptic cleft is markedly slower compared that in
the adult brain [218]. GABA receptor action is normally
inhibitory in the adult brain, but is predominantly exci-
tatory during early brain development due to high intra-
cellular concentrations of chloride as a result of
differential developmental expression of specific chloride
ion transporters [219–221]. During early cortical devel-
opment, experimental models have shown that GABA is
predominantly depolarizing, progressing through child-
hood to the hyperpolarizing state found in the healthy
adult brain [222, 223]. A recent study of experimental
mesial temporal lobe epilepsy found a depolarizing role
of GABA receptor, which was highly upregulated in sur-
viving epileptic neurons [224], suggesting that the early
neurodevelopmental environment may be more vulner-
able to hyperexcitability after an insult. NMDA receptors
are also more permeable to Ca2+ during development
and desensitize more slowly [225]. In addition to a
shorter post-ictal refractory period compared to the
adult brain [226, 227], this inherently increased excitabil-
ity of the pediatric brain may underlie an increased
propensity for PTE after TBI during early childhood.
However, other studies have noted that the immature
brain may conversely show resistance to seizure-related
pathology; for example, chemical stimulation to experi-
mentally induce sustained hyperexcitability is more
difficult in the immature brain [39]. Infant brains may
also be more resistant to excitotoxic-induced cell death
than the adult brain [228]. Due to the apparent paradox
of age-related differences, further study pertaining to the
specific excitability of the developing environment is
needed, particularly in the context of brain injury.
Inflammation in pediatric PTE
As a result of the abovementioned evidence of age-
specific responses to both inflammatory stimuli and
seizures, a potential link between neuroinflammation
and seizure susceptibility particularly during early child-
hood is under intense scrutiny. Experimental studies
have implicated a role for neuroinflammation in in-
creased seizure susceptibility in the immature brain; for
example, exposure to several chemoconvulsant chal-
lenges revealed a lower seizure threshold in immature
rats compared to adults [102]. The authors attribute this
response to increased TNF-α or IL-1β production by
activated microglia in the hippocampus in immature
rats, which was associated with cognitive deficits and
widespread neuronal loss [102, 229]. Changes in seizure
threshold caused by neuroinflammation in the pediatric
brain are associated with long-term alterations in
glutamate receptors in the hippocampus, and a resultant
increase in neuronal network excitability [229, 230].
In addition to the younger brain having an increased
propensity for an enhanced neuroinflammatory
response, age-specific differences in important epilepto-
genic factors have been identified. One such difference is
NMDA receptor density, which has been shown experi-
mentally to peak at p28 at approximately 160% of adult
levels [231]. NMDA receptors also have a different sub-
unit composition in the developing brain compared to
the adult brain, resulting in different functional proper-
ties [232, 233]. Due to these changes, NMDA receptors
are able to depolarize more easily in the presence of
glutamate, resulting in a longer duration of excitatory
postsynaptic currents [218, 234].
Therapeutic targeting of post-traumatic inflamma-
tion to prevent PTE
TBI induces a neuroinflammatory cascade in the brain,
leading to persistent and perpetuating neurodegenera-
tion and likely contributing to an increased risk of initi-
ating epileptogenesis, resulting in the development of
PTE. In the context of the ongoing pursuit of novel
therapeutic targets to prevent PTE, both clinical and
experimental studies provide compelling evidence impli-
cating IL-1β and HMGB1 as pivotal players in the
cascade. Due to their early and varied role in the neu-
roinflammatory cascade after injury and emerging roles
in the regulation of neuronal excitability, pharmaco-
logical targeting of these mechanisms may prove benefi-
cial at reducing PTE. Further pre-clinical studies are
needed to elucidate the exact mechanisms by which
these and other inflammatory mediators initiate or
perpetuate the process of epileptogenesis.
Several different animal models of PTE have been well
studied over the past decade [235]. These experimental
models have demonstrated that TBI results in both acute
and chronic changes to the neuronal environment that
likely contribute to epileptogenesis, such as hyperexcit-
able recurrent circuitry in the dentate gyrus of the
hippocampus [235–237]. Whilst these models allow for
the investigation of various mechanisms and testing of
potential therapeutics, rodent models of PTE are not
without limitations. Some models can produce a high
level of epileptiform activity when measured with
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electroencephalogram, but most models are limited in
the amount of spontaneous seizure activity they induce,
leading to the need for higher animal numbers [11, 238].
One study that used a controlled cortical impact model
of PTE, found that only 20–36% of animals given a
severe TBI developed spontaneous behavioral seizures
[239]. Though this presents logistical challenges, this
incidence is only slightly higher than the estimated inci-
dence in the clinical setting, which one study found to
be 16.7% for severe TBI [240]. Animal models are also
notoriously time-consuming as the latency to spontan-
eous seizure onset can be weeks to months after the ini-
tial injury [238, 241]. To increase the number of animals
that can be investigated in relation to epileptogenesis
and combat time restraints, some studies incorporate
the administration of a pro-convulsant agent, such as
pentylenetetrazol (PTZ), to unveil changes to seizure
threshold as a surrogate marker of seizure susceptibility
[235, 238, 241]. Many neuropathological processes that
occur following TBI, including the neuroinflammatory
response, can also differ greatly due to the developmen-
tal state of the brain at the time of impact [1]. This con-
found should be taken into account when investigating
both the underlying mechanisms of epileptogenesis and
piloting novel therapeutic interventions. Despite these
limitations, these models show high clinical relevance
and are useful tools with which to study PTE, and they
are continually being improved upon.
Much investigation of neuroinflammatory intervention
as a therapeutic option after TBI has focused on broad-
target agents, such as minocycline, erythropoietin, and
progesterone. All of these treatments were proposed to
reduce neuroinflammation after TBI, generating promis-
ing results in pre-clinical research but failing to produce
short-term improvement after TBI during clinical trials,
as reviewed elsewhere [242]. However, these treatments,
which are both pleiotropic in nature and relatively safe
for long-term use, may have more success in relation to
the chronic outcomes such as PTE as many of the
effects of neuroinflammation persist long after the
offending insult, yet few studies have considered the
potential effects of anti-inflammatory treatments on
long-term epileptogenesis after injury. Hypothermia is
another broad-target treatment for neuroinflammation
that has had some success in providing neuroprotection
in the context of TBI and spinal cord injuries, with some
evidence suggesting that it may also prevent epilepto-
genesis [243–245]. The potential to prevent or reduce
PTE by targeting other inflammatory mediators in the
post-injury neural environment, such as serum albumin
and TGF-β, have not yet been explored. Additional
potential targets include TNF-α, which has been shown
to influence neurotransmission by altering excitatory
post-synaptic currents and decreasing GABA-mediated
inhibitory synaptic strength in hippocampal neurons
[246]; the prostaglandin receptor EP2, which mediates
COX-2 inflammatory signaling and appears to promote
seizures by aggravating neuronal injury [247]; as well as
factors involved in regeneration and regrowth such as
fibroblast growth factor, tropomyosin receptor kinase B,
and insulin-like growth factor-1. [248, 249]
Conclusion
This review of the published literature has found that
several inflammatory mediators, including IL-1β and
HMGB1, exhibit epileptogenic and ictogenic properties,
acting on glia and neurons both directly and indirectly
to influence neuronal excitability. As neuroinflammation
is a central component of the neuropathology after TBI,
comparable mechanisms are likely to be involved in the
process of epileptogenesis leading to PTE. An increased
understanding of how inflammation influences epilepto-
genesis may reveal novel therapeutic targets and strat-
egies to prevent or reduce seizures after TBI. As PTE is
often resistant to existing pharmaceutical treatments
[33, 34, 36], there is an urgent need for further research
to develop preventative treatments to improve both the
quality and longevity of life for TBI survivors.
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